In addition to the active ingredient, each capsule contains croscarmellose sodium, povidone K30, pregelatinized starch, sodium stearyl fumarate, and talc.
Antiflu-Des (Antiflu-Des phosphate), an inhibitor of influenza neuraminidase (NAI), is available as:
- Capsules containing 30 mg, 45 mg, or 75 mg of Anti-flu-Despara oral use, in the form of Antiflu-Des phosphate, and a powder for oral suspension, which when constituted with water as indicated, contains 6 mg per ml of the base of Antiflu-Des.
What are the possible side effects of Antiflu-Des?
Stop using Antiflu-Des and seek emergency medical help if you have any of these symptoms of an allergic reaction:
- Difficult breathing
- Swelling of your face
- Tongue or throat
- Red skin rash
- Blisters or peeling
Some people using Antiflu-Des have had rare side effects of:
- Sudden confusion
- Unusual behavior or self-injury
- These symptoms have occurred more frequently in children.
- It is not known if Antiflu-Des was the exact cause of these symptoms.
Indications and doses
Treatment of influenza
Antiflu-Des is indicated for treating acute and uncomplicated diseases caused by influenza A and B in patients two weeks of age or older who have had symptoms no longer than 48 hours.
Prophylaxis of influenza
Antiflu-Des is indicated to prevent influenza A and B in patients one year and older.
Limitations of use
Antiflu-Des is not a substitute for early influenza vaccination annually, as recommended by the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention.
Influenza viruses change over time. The appearance of resistance substitutions could decrease the efficacy of the drug.
Other factors (for example, changes in viral virulence ) may also decrease the clinical benefit of antiviral drugs.
Prescribers should consider the information available on susceptibility patterns to influenza medications and treatment effects.
Administer Antiflu-Des for the treatment of influenza in patients of 2 weeks or more (see Recommended dose for the treatment of flu) or for the prevention of influenza in patients one year and older using:
- Oral suspension (supplied as a powder): This is the preferred formulation (6 mg per ml) for patients who can not swallow the capsules. Before use, the supplied Antiflu-Des powder should be constituted with water by the pharmacist to produce the oral suspension.
Capsules and oral suspension can be taken with or without food; however, if Antiflu-Des is taken with food, tolerability can be improved.
Antiflu-Des capsules can be opened and mixed with sweetened liquids such as regular or unsweetened chocolate syrup, corn syrup, caramel topping, or brown sugar (dissolved in water).
Dosage of treatment
For Treatment Against Influence with Antiflu-Des within 48 hours of flu symptoms for adults and adolescents (13 years of age and older):
- 75 mg twice a day (one 75 mg capsule or 12.5 ml oral suspension twice a day) for five days.
- Pediatric patients (2 weeks of age up to 12 years).
The following serious adverse reactions are discussed below and elsewhere:
- Severe skin reactions and hypersensitivity reactions.
- Neuropsychiatric events.
- Swelling of the face or tongue
- Allergy, anaphylaxis / anaphylactoid reactions.
- Skin and subcutaneous tissue disorders: Skin rash, dermatitis, urticaria, eczema, toxic epidermal necrolysis.
- Stevens-Johnson syndrome.
- Erythema multiforme.
- Gastrointestinal disorders: Gastrointestinal bleeding, hemorrhagic colitis.
- Cardiac disorders: Arrhythmia.
- Hepatobiliary disorders: Hepatitis, abnormal liver function tests.
- Nervous system disorders: Convulsions.
- Metabolism and nutritional disorders: Aggravation of diabetes.
- Psychiatric diseases: Abnormal behavior and delirium, including symptoms such as hallucinations, agitation, anxiety, altered level of consciousness, confusion, nightmares, and delusions.
Do not administer if you use:
- Antacids (magnesium and aluminum hydroxides and calcium carbonates), rimantadine, amantadine, or warfarin.
Influenza can be associated with various neurological and behavioral symptoms that can include events such as hallucinations, delirium, and abnormal behavior, which in some cases result in fatal outcomes.
These events can occur in the setting of encephalitis or encephalopathy, but they can occur without a severe and obvious illness.
Closely monitor patients treated with Antiflu-Des with influenza for signs of abnormal behavior.
If neuropsychiatric symptoms occur, evaluate the risks and benefits of continuing Antiflu-Des for each patient.
Risk of bacterial infections
There is no evidence of the efficacy of Antiflu-Des in any disease caused by other pathogens other than influenza viruses. Severe bacterial infections may begin with flu-like symptoms or may coexist or present as complications during influenza.
Antiflu-Des has not been proven to avoid such complications. Prescribers should be alert to the possibility of secondary bacterial infections and treat them accordingly.
Maternal and embryonic/fetal risk associated with diseases is an increased risk of severe complications of influenza, which can cause adverse pregnancies and fetal outcomes, including maternal death, stillbirths, congenital disabilities, premature births, low birth weight at birth and small for gestational age.